Lund, Sweden based-Paindrainer AB received notification from the European Patent Office that it intends to grant this patent application for its digital tool, Paindrainer, which coaches users in managing their pain and provides guidance on how to reach a personalized activity balance to reach an optimal functional level and alleviate pain.
Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors potentially useful for the treatment of cancer have been described in a recent Scorpion Therapeutics Inc. patent.
Augusta University has patented NSAID derivatives acting as prostaglandin G/H synthase 1 (PTGS1; COX-1) and/or COX-2 inhibitors potentially useful for the treatment of inflammation and pain.
Work at Duke University has led to the discovery of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors potentially useful for the treatment of cancer and gram-negative bacterial infections.
In what represents just the third PCT filing to have been published in the name of Zurich, Switzerland-based Siva Health AG, protection is sought for a computer-implemented method of classifying an individual suffering from chronic cough.
Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK1/cyclin B and/or CDK2/cyclin E1 and/or CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors, reported to be useful for the treatment of cancer.